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Abstract
Sandwich-cultured hepatocytes (SCH) are a powerful in vitro tool that can be utilized to study
hepatobiliary drug transport, species differences in drug transport, transport protein regulation,
drug-drug interactions, and hepatotoxicity. This review provides an up-to-date summary of the
SCH model, including a brief history of, and introduction to, the use of SCH, as well as
methodology to evaluate hepatobiliary drug disposition. A summary of the literature that has
utilized this model to examine the interplay between drug metabolizing enzymes and transport
proteins, drug-drug interactions at the transport level, and hepatotoxicity as a result of altered
hepatic transport also is provided.
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Introduction
Hepatocyte cultures are a widely accepted in vitro tool to evaluate mechanisms of drug
uptake and metabolism, as well as cytochrome P450 induction potential. However, the rapid
loss of many liver-specific functions, redistribution of canalicular membrane proteins, loss
of cell polarity and architecture including bile canaliculi, and the deterioration of cell
viability within several days under conventional culture conditions precludes the use of this
system for long-term studies and measurement of drug excretion (Groothuis et al., 1981,
Borlak and Klutcka, 2004, Luttringer et al., 2002). In contrast, when cultured between two
layers of gelled collagen (i.e. sandwich-cultured configuration) hepatocytes retain more in
vivo-like properties, including formation of intact canalicular networks and polarized
excretory function. Dunn et al. first demonstrated enhanced morphology and viability of
hepatocytes cultured in a sandwich configuration, including normal levels of secretion of
many liver-specific proteins and organic compounds including urea, albumin and bile acids
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(Dunn et al., 1992, Dunn et al., 1989, Dunn et al., 1991). Subsequent studies have
demonstrated that the sandwich configuration facilitates the formation of gap junctions and
functional bile canalicular networks over days in culture (LeCluyse et al., 1994, Liu et al.,
1998).
Many studies have utilized freshly isolated, suspended hepatocytes to examine efflux of
compounds, but this approach is unable to differentiate between sinusoidal efflux and
canalicular excretion (Oude Elferink et al., 1990, Studenberg and Brouwer, 1993, Tarao et
al., 1982). Therefore, hepatocyte suspensions are appropriately restricted to investigating
uptake mechanisms. Canalicular excretion has been studied in hepatocyte couplets, but this
approach is limited to the use of fluorescent substrates (Graf and Boyer, 1990, Mills et al.,
1999). The challenges associated with isolating highly purified fractions of hepatic
basolateral and canalicular liver plasma membrane vesicles with proper orientation has
limited the use of liver plasma membranes as a commonly employed approach to assess
hepatic drug transport. Transfected systems, which are useful for characterizing transport
function, identifying driving forces, and determining substrate specificity and inhibitors, are
routinely used in drug development, although the relative in vivo contribution of a given
protein to hepatic uptake and excretion is difficult to elucidate using current methodologies.
The use of whole organ or in vivo studies may be able to address these fundamental
questions, but typically these are more labor- and animal-intensive approaches with much
lower throughput and greater compound requirements.
Liu et al. were the first to demonstrate that rat sandwich-cultured hepatocytes (SCH) could
be used to investigate the hepatobiliary disposition of substrates (Liu et al., 1999b, Liu et al.,
1999c). Initial work to establish the SCH model system involved optimization and
characterization. Liu et al. investigated the effects of calcium on tight junction integrity and
taurocholate (TC) accumulation in bile canaliculi (Liu et al., 1999c). This work
demonstrated that tight junctions were the major diffusional barrier between the canalicular
lumen and the extracellular space in SCH; tight junctions could be disrupted rapidly (within
3 min) by depletion of extracellular calcium without altering TC transport. Further work
demonstrated that relevant hepatic transport proteins were expressed and properly localized
in rat SCH (Turncliff et al., 2004, Hoffmaster et al., 2004, Zhang et al., 2005b), and were
induced by well-established modulators such as dexamethasone (DEX) (Turncliff et al.,
2004). P-glycoprotein (P-gp) co-localized with the canalicular marker protein dipeptidyl
peptidase IV in day 4 and 6 rat and human SCH, respectively (Hoffmaster et al., 2004).
Zhang and colleagues demonstrated by confocal microscopy that day 4 rat SCH exhibited
extensive canalicular networks and distinct canalicular and basolateral domains, as
evidenced by immunofluorescent localization of multidrug resistance-associated proteins 2
(Mrp2) and Mrp3, respectively. As clearly shown in Fig. 1, Mrp2 localized to the tubular
structures of the bile canaliculi (green) and did not co-localize with the red staining in the
basolateral membrane (Mrp3). Results of studies suggested the involvement of glycosylation
in directing the canalicular localization of Mrp2 (Zhang et al., 2005b). A plethora of work
has established the function of numerous hepatic uptake and efflux proteins in rat and
human SCH. In vitro intrinsic biliary clearance values generated for compounds in SCH, and
scaled biliary clearance values, correlate well with in vivo biliary clearance data measured
with the same compounds in rats (Abe et al., 2008, Liu et al., 1999a, Fukuda et al., 2008)
and humans (Abe et al., 2009, Ghibellini et al., 2007) (Fig. 2).
Another useful application of this model is in assessing human hepatobiliary drug
disposition and hepatic transporter-based drug-drug interactions (DDI). However, the lack of
fresh, healthy human liver tissue suitable for hepatocyte isolation and culture is a significant
limitation. Fortunately, the establishment of commercially available, cryopreserved human
hepatocytes that retain properties conducive for plating and culturing has expanded the use
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of this model (Bi et al., 2006). The use of cryopreserved hepatocytes is a significant
advantage that allows for greater access to hepatocytes and the ability to conduct routine
studies on demand. Applications of this model have been extended to include hepatocytes
from other species. The predominant non-rodent species used in preclinical development are
dog and monkey. Methods have been established to culture dog and monkey primary
hepatocytes in a sandwich configuration (Fig. 3) (Rose et al., 2006, Zhang, 2005), which
could be particularly useful in examining species differences in the hepatobiliary disposition
of compounds, adverse hepatotoxic events, and/or unexpected pharmacokinetic data. Higher
throughput screening systems, such as mouse SCH, may prove to be particularly useful for
unraveling the physiological, pharmacological and toxicological roles of hepatic proteins
utilizing hepatocytes from gene-disrupted mice, and the phenotypic diversity offered by
various mouse strains such as the Collaborative Cross (Threadgill et al., 2002). Towards that
end, recent efforts have focused on optimizing conditions for culturing mouse hepatocytes in
a sandwich configuration (Fig. 4) (Swift and Brouwer, 2010).
Methodology
Considerable effort by many investigators has been devoted to describing the influence of
numerous culture conditions on hepatocyte viability, morphology, function and growth. A
complete discussion of the effects of culture media, supplemental soluble factors, chemical
modulators, and extracellular matrix on hepatocytes is beyond the scope of this review [see
published reviews (LeCluyse et al., 1996, Ichihara et al., 1982, Rogiers and Vercruysse,
1993)]. Detailed below is a brief review of just a few of the many factors that influence the
optimization of canalicular network formation, as well as transport protein expression and
function in hepatocytes that are already in a differentiated state, specifically for purposes of
studying hepatobiliary disposition.
It is well understood that plating hepatocytes onto inflexible or rigid substrata such as plastic
or simple protein coatings, typical of conventional cell culture conditions, is not conducive
to normal expression of liver-specific and cytochrome P450 genes (Reid and Jefferson,
1984). Therefore, liver-specific extracellular matrix proteins such as collagen (types I–IV),
laminin, fibronectin, and heparin sulfate proteoglycans were evaluated as potential substrata
in culture (Stamatoglou and Hughes, 1994, Reid et al., 1992). Results from various studies
demonstrated type I and IV collagen were superior to fibronectin and laminin (Sudhakaran
et al., 1986, Bissell et al., 1986, Sawada et al., 1987). Further studies focusing on collagen
demonstrated that hepatocytes plated between layers of gelled type I collagen maintained a
three-dimensional cuboidal shape and distribution of cytoskeletal proteins similar to that
observed in vivo whereas hepatocytes grown on ungelled collagen flattened and spread to
confluence (Rubin et al., 1981, Lindblad et al., 1991). Other types of substrata also have
been used successfully to culture hepatocytes including biomatrix (Rojkind et al., 1980), a
complex, partially-purified extract of extracellular matrix material prepared from normal rat
liver, and Matrigel™ (Bissell et al., 1987), an acid-urea extract prepared from Engelbreth-
Holm-Swarm tumor tissue excised from lathyritic mice (Kleinman et al., 1982, Orkin et al.,
1977).
In addition to extracellular matrix, investigators also have focused on determining the
critical components in media that are responsible for enhancing hepatocyte function and
viability. The effects of various media supplements such as amino acids, hormones, growth
factors, vitamins, trace elements and other cofactors on hepatocyte function and viability in
primary culture have been described extensively (Berry et al., 1991, Dich and Grunnet,
1989, Guguen-Guillouzo and Guillouzo, 1983). A large variety of commercially available
media formulations have been employed for culturing primary hepatocytes including
Waymouth's MB-752/1, Ham's F12, RPMI 1640, Dulbecco's modified Eagle's medium,
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Williams' medium E, Leibovitz' L15 and modified Chee's medium. The use of highly
enriched media such as modified Chee's medium and Leibovitz' L15, which contain amino
acid concentrations that are 5–10 times higher than most standard media, are superior for
maintenance of cell survival, preserving cellular protein levels and liver specific functions
(Jauregui et al., 1986, Sawada et al., 1987). Higher levels of amino acids have been
suggested to aid in recovery of hepatocytes following collagenase digestion, arrest
lysosomal protein degradation (Jauregui et al., 1988), and inhibit the rate of autophagic
protein and RNA degradation while stabilizing the activity of some liver specific enzymes
(Balavoine et al., 1993, Hutson et al., 1987, Lee et al., 1992, Seglen et al., 1980).
Collectively, the results of these studies emphasize the importance of supplementing
standard media with various commercially-available amino acid formulations. For example,
Brouwer and co-workers supplement Dulbecco's modified Eagle's medium with L-glutamine
and MEM non-essential amino acids solution (Invitrogen, Carlsbad, CA).
Culture media also have been supplemented with serum, based on reported findings
following early attempts to culture rat hepatocytes in vitro (Bissell et al., 1973, Bonney et
al., 1974) demonstrating that serum improves cell attachment, survival and morphology
(Williams et al., 1977). However, serum has a dedifferentiating effect on hepatocytes,
inhibits the induction effects of phenobarbital, inhibits the re-establishment of bile
canaliculi, and favors attachment of non-parenchymal cells (Clayton and Darnell, 1983, Enat
et al., 1984, Jefferson et al., 1984, Waxman et al., 1990, Terry and Gallin, 1994).
Hepatocytes cultured on an extracellular matrix such as Matrigel™, or in co-culture with
other cell types that promote a differentiated state, do not exhibit the same serum effects as
those maintained on simple rigid substratum (Dunn et al., 1991, Guguen-Guillouzo et al.,
1983, Ichihara, 1991, Vandenberghe et al., 1988, LeCluyse et al., 1994, Chandra et al.,
2001). Other important supplements include the addition of hormones such as DEX and
insulin. DEX increases secretion of blood clotting factors which aggregate into fibrin
meshworks that are resistant to urea, promotes an ordered arrangement of the cytoskeleton,
enhances gap junction expression and function, supports cytochrome P450 activity, curtails
decreased protein synthesis that is observed during the first 24 h in culture, and enhances the
formation of bile canalicular networks (Arterburn et al., 1995, Forster et al., 1986,
Kwiatkowski et al., 1994, Ren et al., 1994, Lambiotte et al., 1973, LeCluyse et al., 1994).
Insulin is reported to improve survival and attachment, enhance amino acid transport,
protein synthesis, glycogenesis and lipogenesis; insulin also inhibits protein degradation and
potentiates the inhibition of RNA degradation by amino acids (Balavoine et al., 1993,
Ballard et al., 1980, Chapman et al., 1973, Laishes and Williams, 1976, Dahn et al., 1993,
Flaim et al., 1985, Guguen-Guillouzo and Guillouzo, 1983, Schwarze et al., 1982).
Optimization of bile canalicular network formation in SCH is critical for studying
hepatobiliary disposition and accurately assessing biliary excretion. Chandra et al. refined
culture conditions for determining the hepatobiliary disposition of TC in rat SCH by
evaluating the time of collagen overlay, the volume of collagen (rat tail type I), media type,
and media additives (Chandra et al., 2001). Results demonstrated that Williams' medium E
and Dulbecco's modified Eagle's medium produced greater taurocholate accumulation and
biliary excretion compared to modified Chee's medium. Other parameters, such as time and
volume of collagen overlay, Dulbecco's modified Eagle's medium additives such as 5% fetal
bovine serum or DEX (0.1 μM versus 1 μM) did not produce significant differences in
taurocholate accumulation or biliary excretion (Chandra et al., 2001). A separate study
investigated the effects of culture conditions such as extracellular substratum, culture
medium, and cell density on the expression and function of the bile salt export pump (Bsep),
Mrp2, and multidrug resistance 1 (Mdr1a/b, P-glycoprotein, P-gp) in rat SCH (Turncliff et
al., 2006b). In general, protein expression and function were not influenced by the
extracellular matrices examined (rat tail gelled collagen type I vs. Biocoat™). Similar to the
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findings of Chandra et al., Williams' medium E and Dulbecco's modified Eagle's medium,
compared to modified Chee's medium, resulted in greater function of Bsep, Mrp2 and
Mdr1a/b based on hepatocellular accumulation and biliary excretion of taurocholate, 5(and
6)-carboxy-2',7'dichlorofluorescein (CDF), and rhodamine 123. Decreasing seeding density
from 100% confluency significantly altered Mrp2 and Mdr1a/b expression and/or function
(Turncliff et al., 2006b). Work by Zhang and colleagues investigated the influence of 6-, 12-
and 24-well plates, three different types of media [Williams' medium E, Dulbecco's
modified Eagle's medium, and hepatocyte maintenance medium (Cambrex Corporation,
Baltimore, MD)], and two different extracellular matrix substrata [gelled collagen (rat tail
type I) under- and overlay (GC/GC) and Biocoat™ (collagen type I, BD Biosciences,
Bedford, MA) with Matrigel™ (BD Biosciences, Bedford, MA) overlay (BC/MG)] on
transport protein function and expression in fresh, primary human SCH (Zhang et al.,
2005a). Various media types and plate formats resulted in no difference in the biliary
excretion of the probe substrates taurocholate, digoxin, estradiol-17-β-D-glucuronide and D-
penicillamine2,5enkephalin. BC/MG yielded higher attachment and increased levels of P-gp,
Bsep and Mrp2 protein compared to GC/GC. The use of Biocoat™ plates with Matrigel™
overlay has the additional advantage of uniformity, due to the lack of interindividual
differences in manual coating with gelled collagen. Further work with cryopreserved human
(Bi et al., 2006) and freshly isolated mouse hepatocytes (Bi et al., 2006, Swift and Brouwer,
2010) has confirmed the superiority of the BC/MG combination. Interestingly, dog
hepatocytes cultured on Biocoat™ plates and overlaid with an alkaline gelled collagen (rat
tail type I; pH 9.0) resulted in increased excretion of taurocholate compared to physiologic
pH 7.4 (Rose et al., 2006).
There are many other parameters in addition to media type/components and extracellular
matrix to consider when culturing hepatocytes in a sandwich configuration for hepatobiliary
transport studies. The extent of bile canalicular network formation and optimal levels of
metabolizing enzymes and transport proteins are important factors to consider when
determining the appropriate time in culture to conduct functional studies. LeCluyse et al.
showed the development of bile canaliculi in rat SCH during the first 24–48 h, followed by a
more uniform and homogeneous network through days 3–7; canalicular networks were
maintained for at least 2–3 weeks (LeCluyse et al., 1994). The biliary excretion of TC
increased and reached a maximum value four days after overlay of rat hepatocytes (Liu et
al., 1999b). Likewise, the biliary excretion of [D-penicillamine2,5]enkephalin, a good P-gp
substrate, increased up to day 4 after overlay and then started to decrease (Hoffmaster et al.,
2004). The levels of many hepatic transport proteins in rat and human SCH over days in
culture have been determined (Fig. 5); proper localization of Mrp2 and Mrp3 (Fig. 1), as
well as P-gp have been investigated at day 4 after overlay in rat SCH (Hoffmaster et al.,
2004, Zhang et al., 2005b). The dynamic process of canalicular network formation may take
longer for human SCH, which are typically cultured for up to 6–10 days after overlay. The
opposite is true for mouse hepatocytes, in which optimal cell morphology and biliary
excretion of TC and CDF occurred on day 3 after overlay (Swift and Brouwer).
Cell density influences the morphology of hepatocytes in culture and is important for cell-
cell contact (Hamilton et al., 2001). The confluency of hepatocytes cultured in a sandwich
configuration is also crucial to the induction response. Initially, cryopreserved hepatocytes
were unsuitable for induction studies because of their low attachment efficiency and poor
quality. A great deal of emphasis has been placed on improving cryopreservation techniques
to enhance the quality of hepatocytes and increase recovery and attachment. Greuet et al.
demonstrated that maintaining primary human hepatocytes at a low density in the presence
of epidermal growth factor (promoting proliferation and dedifferentiation) reduced the
ability of the cells to respond to the prototypical inducer rifampin (Greuet et al., 1997).
Decreased seeding densities of human hepatocytes to yield confluencies of 50, 30 and 25%
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of normal caused a decrease in the induction of CYP3A4 by 10 μM rifampin, as measured
using the probe substrate testosterone; decreased seeding density also changed the
phenotype of the hepatocytes resulting in more fibroblast-like (de-differentiated)
characteristics (LeCluyse, 2001). Furthermore, Turncliff et al. demonstrated that a decrease
in seeding density from 100% confluency resulted in decreased Mrp2 and Mdr1a/1b
expression and/or function (Turncliff et al., 2006b). See Table 1 for a summary of
recommended seeding densities based on the literature and experience by Brouwer and
coworkers.
Hepatobiliary disposition is evaluated on a specific day (or range of days) in culture based
on optimal canalicular network development in each species. Two different protocols using
B-CLEAR® technology (U.S. Pat. No. 6,780,580, Pat. No. 7,604,934 and other US and
International patents both issued and pending) to quantify hepatic uptake and biliary
excretion are discussed below; calcium depletion is utilized to disrupt the tight junctions and
subsequently rinse the bile canalicular networks.
Accumulation Studies
This protocol involves initial incubation of SCH with Hanks' Balanced Salts solution
(HBSS) containing Ca2+ (standard HBSS) or Ca2+-free HBSS for 10 min [to maintain tight
junction integrity and bile canalicular networks, or disrupt tight junctions and open bile
canalicular networks, respectively (Fig. 6)]. Accumulation of taurocholate and CDF in rat
SCH was reduced within one to two minutes following incubation with Ca2+-free HBSS
(Liu et al., 1999b, Liu et al., 1999c). The bile canalicular space also was reduced based on
phase contrast microscopy after a 10-min incubation with Ca2+-free HBSS (Liu et al.,
1999c). Following the 10-min preincubation, buffer is removed and all cells are incubated
with substrate(s) in standard HBSS for a predetermined period of time based on the substrate
(time and concentration should be within the linear range of uptake, preferably within the
first 10 to 15 min). This short-term accumulation phase should be conducted in standard
HBSS to prevent potential interference due to the absence of Ca2+ on substrate uptake in
SCH. Subsequently, SCH are rinsed three times with ice-cold standard buffer, lysed, and
lysate is subjected to analysis for determination of substrate accumulation, by scintillation
counting, high-performace liquid chromatagraphy (HPLC) or liquid chromatography
coupled with tandem mass spectrometry (LC/MS/MS) in cells+bile (hepatocytes
preincubated in standard HBSS) and cells (hepatocytes preincubated in Ca2+-free HBSS).
Liu et al. demonstrated that rat SCH incubated for 10 min in Ca2+-free HBSS followed by
incubation in Ca2+-containing HBSS exhibited gradual restoration of bile canalicular
accumulation of taurocholate, reaching ~80% of standard HBSS-treated cells after 60 min;
canaliculi re-dilated based on phase contrast microscopy (Liu et al., 1999c). Optimal study
design should take into account the possibility that measurable substrate may begin to
accumulate in bile canaliculi of SCH preincubated in Ca2+-free HBSS within 30 min
following exposure to Ca2+-containing HBSS due to re-establishment of tight junction
integrity. Furthermore, as discussed below, incubation of rat SCH in Ca2+-free HBSS for
more than 30 min causes increased cell death.
The intracellular concentration of a given substrate may be estimated from the accumulated
mass and the hepatocellular volume. The average hepatocellular volume of rat SCH in 6-
well and 24-well plates was 6.2 × 10−6 μl/hepatocyte, determined using 3-O-methyl-D-
glucose, a metabolically stable hexose that is transported across cell membranes by
facilitated diffusion [(Uhal and Roehrig, 1982), Jin K. Lee, personal communication,
Qualyst, Inc., Durham, NC].
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Hepatic uptake clearance of substrates may be quantified based on the total accumulation of
substrate in standard HBSS in the linear range of uptake according to the following
equation:
(1)
where AUC0-T represents the product of the incubation time (T) and the initial concentration
in the medium, assuming that the concentration at T is not less than 10% different from the
initial concentration. In the absence of sink conditions, the AUC should be calculated based
on the log-linear trapezoidal method.
Using B-CLEAR® technology, the biliary excretion index (BEI) of substrates may be
quantified based on the fraction of accumulated substrate that resides in the bile canaliculi
using the following equation:
(2)
and in vitro biliary clearance (Clbiliary) may be quantified based on the total accumulation of
substrate in the bile canalicular networks divided by the area under the concentration curve
of the dosing medium using the following equation:
(3)
In vitro Clbiliary values can be scaled to per kilogram of body weight, depending on the
species (see Table 2). In vitro Clbiliary values have been shown to correlate well with in vivo
intrinsic Clbiliary values in rats and humans for a number of compounds (Fig. 2) (Yue et al.,
2009, Abe et al., 2008, Ghibellini et al., 2007, Liu et al., 1999a, Fukuda et al., 2008). Use of
the well-stirred model for scaling Clbiliary, expressed as μL/min/million cells, to in vivo
hepatic clearance, expressed as mL/min/kg body weight, has been shown to correlate well in
rats (Abe et al., 2008).
Inhibitors may be added during the preincubation phase in standard and Ca2+-free HBSS to
preload the hepatocytes with inhibitor, and/or added during the substrate uptake phase in
standard HBSS. However, depending on the inhibitor, modulation of substrate disposition
may be due to inhibition of uptake, and/or inhibition of basolateral and/or canalicular efflux,
making the results difficult to interpret. Inducers may be added to the culture medium for
specified periods of time prior to conducting uptake studies. In order to avoid direct effects
of the inducer or inhibitor on substrate uptake, a modulator-washout phase may be
necessary, and modulators also may need to be removed from the standard HBSS buffer
during the uptake phase.
Efflux Studies
Compared to the accumulation protocol, basolateral and canalicular efflux studies in SCH
are defined by the reversal of substrate incubation and tight junction disruption steps. This
efflux approach was first evaluated by Liu (Liu et al., 1999b), and has been utilized by
Kostrubsky and colleagues as well as Jemnitz and coworkers in a number of studies (Feng et
al., 2009, Kostrubsky et al., 2006, Lengyel et al., 2005, Lengyel et al., 2008). First, the
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substrate of interest is incubated with SCH in standard HBSS to preload the cells. The
loading phase is stopped by removing the buffer and washing hepatocytes three times with
warm standard HBSS or Ca2+-free HBSS. Efflux studies are initiated by incubating
preloaded hepatocytes with their respective buffers; aliquots are taken at designated time
points for no longer than 30 min (Fig. 7). If inhibitor(s) are included in the incubation during
the efflux phase, the amount of substrate in the lysed SCH at the end of the efflux phase
must be measured in addition to the amount of substrate in the aliquots in order to evaluate
potential modulation of the transport of the preloaded substrate. The degree of basolateral
and canalicular efflux can be determined based on the following equations:
(4)
(5)
In both cases, if multiple samples of HBSS buffer are taken over a period of time, the
change in volume needs to be accounted for based on the number and volume of aliquots
taken. Both basolateral and canalicular efflux values can be normalized to the total amount
of pre-loaded substrate using the sum of the total mass in the efflux medium and hepatocyte
lysate at the end of the efflux phase.
There are several caveats that must be considered when designing efflux experiments and
interpreting the results. First, it is imperative that the incubation with Ca2+-free HBSS is for
a limited period of time (e.g., not greater than 30 min). Omission of extracellular Ca2+ from
cells incubated with a buffered salt solution is known to result in cell death (Reed et al.,
1990); rat SCH incubated in Ca2+-free HBSS exhibited a significant increase in lactate
dehydrogenase (LDH) leakage within 30 min (Fig. 8). Another limitation to this method is
the unknown degree of substrate accumulation in the bile canaliculi during the preloading
period, which is not washed away when transport is stopped and dosing solutions are
removed. This may result in an overestimate of canalicular efflux. If chemical inhibitors of
active transport processes are added during the substrate preloading phase, as discussed
above, decreased efflux may be due to impaired uptake and/or efflux; evaluation of the sum
of the total mass in the efflux medium and hepatocyte lysate in the absence and presence of
inhibitor(s) would be required to distinguish between these two possibilities. Alternatively,
inhibitor(s) could be added after the preloading step to avoid potential interference with the
uptake process when concomitantly incubated. However, the time required for the
inhibitor(s) to reach the site of transport inhibition must be considered in this study design.
As mentioned with the accumulation protocol, perturbations in substrate disposition
observed during the efflux period may be due to inhibition of basolateral or canalicular
efflux, as well as to inhibition of substrate re-uptake. Another consideration is that medium
concentrations may be influenced significantly by basolateral efflux of substrate during the
efflux phase due to the reversal of the concentration gradient. In contrast, basolateral efflux
of substrate would be expected to have minimal effects on medium concentrations in the
accumulation protocol due to sink conditions.
The use of chemical inhibition to investigate the role of specific transport proteins in the
disposition of substrates is widely used and accepted. It is not the most precise method,
however, due to incomplete knowledge about the specificity of inhibitors for individual
transport proteins. Naturally occurring genetically-deficient rodents lacking a specific
transport protein such as the Mrp2-deficient Wistar (TR−) and Eisai hyperbilirubinemic
Sprague-Dawley rats (EHBR), and the Mdr1a-deficient CF-1 mice, have been useful tools
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for elucidating the role of these transport proteins in the disposition of endogenous
compounds and xenobiotics; incorporation of hepatocytes from these mutants in the
sandwich-cultured model has been of great utility. Abe and colleagues confirmed in vivo
reports that olmesartan, valsartan, pravastatin and rosuvastatin were Mrp2 substrates by
demonstrating that SCH from TR− rats exhibited decreased BEI and in vitro Clbiliary relative
to SCH from transport-competent Wistar controls (Abe et al., 2008). Interestingly,
pitavastatin BEI was reduced despite previous data demonstrating that the in vivo biliary
excretion of pitavastatin was similar in wild-type and EHBR rats (Hirano et al., 2005).
Further investigation revealed a novel finding: breast cancer resistance protein (Bcrp) levels
were considerably lower in SCH from TR− rats compared to Wistar control rats based on
immunoblot analysis (Abe et al., 2008). Many transport proteins have been knocked out
alone or in combination in mice using various gene disruption techniques. However, mouse
SCH have not been investigated as extensively as rat or human SCH, and mouse hepatocytes
are known to be more difficult to maintain in culture.
RNA interference (RNAi) leads to post-transcriptional, sequence-specific gene silencing and
is a powerful tool to study the effect of loss-of-function of genes. The application of this
technology to suppress specific transport proteins in SCH (U.S. Pat. No. 6,780,580, Pat. No.
7,601,494 and other US and International patents both issued and pending) has provided
another tool, in addition to knockout mouse models, to gain insight into the function of
specific transport proteins. Brouwer and coworkers successfully applied this approach using
small interfering RNA (siRNA) targeting Mrp2 and Mrp3; protein levels were decreased by
~50% in rat SCH, and Mrp2 and Mrp3 function also was decreased based on the
hepatobiliary disposition of CDF, a probe substrate for both transport proteins (Tian et al.,
2004). More recently, Brouwer and coworkers have used adenoviral vector-mediated
delivery of short hairpin (sh) RNA to knock down Bcrp in rat and human SCH; decreased
expression and function have been confirmed using the probe drug, nitrofurantoin (Yue et
al., 2009).
Another unique tool that has been utilized with the SCH model system is incubation with
fluorescent probes to study transport protein expression, localization and function. CDF and
cholyl-lysyl-fluorescein (CLF), a fluorescent bile acid, have been used to visualize the
development of bile canalicular networks over days in culture (Kostrubsky et al., 2003, Liu
et al., 1999b, LeCluyse et al., 1994, Zhang et al., 2005b, Bi et al., 2006). CDF accumulated
in the canalicular networks of SCH from C57BL/6 wild-type but not Abcc2−/− (Mrp2
knockout) mice (Fig. 6), demonstrating the important role of Mrp2 in the biliary excretion of
CDF. Ruthenium red staining also has been used to demonstrate that the bile canaliculi are
sealed until Ca2+ depletion disrupts the tight junctions (Liu et al., 1999c). An important
advantage of fluorescent probe substrates is the straightforward quantification by
fluorescence spectroscopy. CDF diacetate (2 μM) has been used to phenotype the function
of Mrp2 and Mrp3 after siRNA knockdown in rat SCH, as mentioned above (Tian et al.,
2004). Rhodamine 123, a model P-gp substrate, has been used in rat SCH to assess P-gp-
mediated biliary excretion, and to examine drug interactions affecting P-gp function
(Annaert and Brouwer, 2005, Annaert et al., 2001). Cholyl-glycylamido-fluoroscein
(CGamF) is a fluorescent bile acid that preferentially undergoes organic anion transporting
polypeptide (Oatp)-mediated hepatic uptake, as opposed to taurocholate, which is
predominantly Sodium taurocholate cotransporting polypeptide (Ntcp)-mediated. CGamF
was used recently to assess drug interactions in hepatic uptake with the HIV protease
inhibitors ritonavir, saquinavir, atazanavir, darunavir, and amprenavir in rat SCH (Ye et al.,
2008). To date, application of fluorescent probes has focused primarily on characterizing
hepatobiliary transport function and transporter-based DDIs. Fluorescent probe substrates, or
fluorescence-tagged xenobiotics, may be useful in the future to elucidate mechanisms of
intracellular trafficking of xenobiotics. For example, the innate fluorescence of the cation,
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daunorubicin, was utilized to demonstrate the intracellular sequestration of daunorubicin in
vesicles in the pericanalicular region of rat isolated perfused livers (IPLs) and isolated rat
hepatocyte couplets (Hayes et al., 1999). Other work has shown the expression of functional
P-gp when localized to the Golgi and mitochondria of doxorubicin-resistant K562 cells
(Munteanu et al., 2006). This supports the hypothesis that other transport proteins may
reside at intracellular sites and play a role in xenobiotic distribution within the hepatocyte.
This could be investigated with the use of the sandwich-cultured model system.
Use of Sandwich-Cultured Hepatocytes to Investigate the Interplay
Between Drug Metabolism and Transport
The liver plays a major role in the biotransformation of many endogenous and exogenous
compounds, and also represents an important target organ for toxicity. Hepatic cell lines,
precision-cut liver slices, and primary hepatocyte cultures from various species represent
predominant and well-established in vitro systems for conducting these studies. Advantages
of intact hepatocytes include the presence of: (1) interacting enzyme systems, intracellular
machinery and physiological concentrations of cofactors allowing for coupled phase I and
phase II reactions to take place; (2) the entire array of hepatic transport proteins involved in
hepatic uptake and excretion, some of which may limit access to the site of metabolism; and
(3) nuclear receptors, which allow regulation and induction of enzymes and transport
proteins. The sandwich-cultured configuration is important for maintaining the differentiated
morphology of hepatocytes and longevity in culture (Tuschl and Mueller, 2006). The major
limitation to using hepatocyte cultures to study drug metabolism is the decline in
cytochrome P450 enzyme activity (Hoen et al., 2000, Boess et al., 2003), although medium
additives can help maintain function, as detailed below. Despite this, sandwich-cultured
primary hepatocytes remain a well-established model for induction studies due to the lack of
phenotypic gene expression in nearly all immortalized cell lines and the short-term viability
of liver slices (LeCluyse, 2001).
In order to reverse the decline of cytochrome P450 enzymes, well known inducers such as
phenobarbital and DEX have been added as medium supplements, separately or in
combination (LeCluyse et al., 1996, Miyazaki et al., 1998, Pichard-Garcia et al., 2002). The
addition of phenobarbital, DEX and β-naphthoflavone to the culture medium of rat SCH
preserves phase I and II enzyme levels almost equivalent to those in liver in vivo, as
determined by gene expression and enzyme activity analysis (Kienhuis et al., 2007). A
discussion of the expression and function of phase I and phase II biotransformation enzymes
in SCH is beyond the scope of this paper, but has been reviewed by many others (Hewitt et
al., 2007a, Hewitt et al., 2007b, LeCluyse, 2001, Rogiers and Vercruysse, 1993, Maurel,
1996, Ferrini et al., 1997). The current review will focus on the interplay between drug
metabolism and disposition of the parent and preformed or generated metabolites in the
sandwich-cultured model system.
It is not surprising that interplay exists between transport proteins and metabolizing enzymes
due to the common regulatory pathways mediated by the nuclear receptors, and the substrate
overlap of the parent compound and/or generated metabolites for the transport proteins. The
most well-studied example of this interplay is the common regulation and substrate/inhibitor
overlap between P-gp and CYP3A4 (Wacher et al., 1995, Yasuda et al., 2002). This
coordinated clearance pathway has been examined in rat SCH using the drug/metabolite pair
terfenadine, a known CYP3A4 substrate (Yun et al., 1993, Jurima-Romet et al., 1994), and
fexofenadine, both known P-gp substrates (Hait et al., 1993, Cvetkovic et al., 1999).
Turncliff et al. determined the metabolism of terfenadine as well as the basolateral efflux
and biliary excretion of terfenadine and fexofenadine (both preformed and generated) in
control and DEX-treated rat SCH (Turncliff et al., 2006a). Treatment with 100 μM DEX
Swift et al. Page 10













increased the formation rates of the terfenadine metabolites, azacyclonol and fexofenadine,
approximately 20- and 2-fold, respectively. Pharmacokinetic modeling of the data indicated
that the rate constant for hepatocyte uptake was faster for terfenadine compared with
preformed fexofenadine (2.5 vs. 0.08 h−1, respectively), whereas the biliary excretion rate
constant for preformed fexofenadine exceeded that of terfenadine (0.44 vs. 0.039 h−1,
respectively). The rate constants for basolateral excretion of terfenadine and fexofenadine
were comparable (3.2 vs. 1.9 h−1, respectively) (Turncliff et al., 2006a). This study
emphasizes the utility of the SCH model as an in vitro system capable of assessing, in an
integrated fashion, metabolism, biliary excretion, and basolateral transport processes.
Rat SCH have been used to compare the hepatobiliary disposition of two orally active
pentamidine analogues, and pharmacokinetic modeling has been utilized to examine the
rates of hepatic uptake, metabolism, biliary excretion and basolateral efflux (Yan et al.,
2008). Conversion of pafuramidine to the active metabolite, furamidine, is catalyzed by
cytochrome b5/NADH-cytochrome b5 and many CYP450 enzymes, notably CYP4F (Wang
et al., 2006, Saulter et al., 2005). The purpose of these studies was to determine the
mechanism(s) responsible for the improved efficacy of DB868, an analog of the prodrug
pafuramidine, in a late-stage mouse model of African trypanosomiasis. DB829, the active
metabolite of DB868, has a higher systemic exposure, due either to increased metabolism
and/or increased hepatic basolateral efflux of the active metabolite. The extent of formation
of the active metabolite DB829 was consistently higher than that of furamidine over time in
rat SCH. In addition, the net hepatic basolateral efflux was greater for DB829 compared to
furamidine, consistent with pharmacokinetic modeling in which the rate constant
representing basolateral efflux was increased 6-fold for DB829 compared to furamidine
(Yan et al., 2008).
The examples given above involve phase I oxidation reactions, but additional examples have
focused on the formation and hepatobiliary disposition of phase II conjugates. Wolf et al.
characterized the accumulation, glucuronidation and excretion of morphine in rat SCH
(Wolf et al., 2008). In vitro data were in good agreement with in vivo data indicating that
morphine 3-glucuronide (M3G) was the primary metabolite formed (Wolf et al., 2008). In
rat SCH, M3G was eliminated across the basolateral membrane; ~99% of the drug-related
mass was recovered in medium during the 120-min study as M3G. M3G reuptake in rat
SCH appeared to be negligible based on pharmacokinetic modeling, consistent with findings
in the rat IPL when preformed M3G was administered (Doherty et al., 2006, Ouellet and
Pollack, 1995). Another example of glucuronidation in rat SCH is with the opioid antagonist
naloxone (Ansede and Brouwer, 2008). Following incubation of 10 μM naloxone for 80
min, less than 1% of naloxone was recovered in the hepatocytes or bile canaliculi; 89.3% of
the dose was recovered as naloxone 3-glucuronide in medium (Ansede and Brouwer, 2008).
This is consistent with in vivo rat studies demonstrating that naloxone glucuronide is the
major metabolite, with 15.4 and 1.2% of naloxone 3-glucuronide recovered in urine and
feces, respectively, after 96 hr (Misra et al., 1976). SCH from both humans and rats also are
capable of forming other conjugates based on data generated utilizing troglitazone (Lee et
al., 2010). Troglitazone sulfate was the predominant metabolite in medium and hepatocytes,
followed by troglitazone glucuronide and troglitazone quinone, over a 120-min incubation
period with 10 μM troglitazone in rat and human SCH. Similar to in vivo, the biliary
excretion of trogitazone sulfate was greater than troglitazone glucuronide, while troglitazone
and troglitazone quinone underwent negligible biliary excretion in rat and human SCH (Loi
et al., 1999a, Loi et al., 1999b). The impact of modulating the biliary excretion of
troglitazone sulfate and troglitazone glucuronide on hepatic accumulation was assessed
utilizing a Monte Carlo simulation approach. Interestingly, changes in hepatocyte
concentrations were more sensitive to changes in biliary excretion than medium
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concentrations, suggesting that plasma concentrations may not reflect increased liver
accumulation and the potential for hepatotoxicity in vivo (Lee et al., 2010).
Evaluation of other substrate/metabolite pairs undergoing biotransformation by phase I and/
or II enzymes, and further characterization of the biliary elimination of unchanged
compounds and generated metabolites, will enhance understanding of the utility of this
model system. Mass balance data detailing the parent compound and generated metabolites
in medium, cells and bile canaliculi, coupled with pharmacokinetic modeling, can provide a
robust evaluation of the hepatobiliary disposition of compounds, including relative rates for
the hepatic uptake, metabolism, basolateral efflux and biliary excretion of the parent
compound and generated metabolites. The SCH model offers the ability to quantify the
impact of modulation of both hepatic transport systems and metabolism of drugs on overall
disposition in a single in vitro system, which has significant advantages over existing
methodologies.
Sandwich-Cultured Hepatoctyes as a Tool to Predict Drug Interactions in
Hepatobiliary Transport
Inhibition of Bile Acid Transport by Drugs
Vectorial transport of bile acids from the blood into bile is a multistep process starting with
uptake into hepatocytes, mediated predominantly by NTCP (SLC10A1), with a minor
component mediated by OATP (SLCO) isoforms. Bile acids are effluxed from hepatocytes
into bile, in conjugated or unconjugated form, by canalicular ATP-binding cassette (ABC)
transport proteins, primarily ABCB11 (BSEP), but also by ABCC2 (MRP2) and others
(Marion et al., 2007). Basolateral excretion of bile acids from hepatocytes into blood is
mediated by MRP3 (ABCC3) and MRP4 (ABCC4), providing a compensatory pathway
under certain conditions, such as cholestasis or inhibition of canalicular excretion. The
organic solute transporter (OSTα/β) recently was identified as another basolateral transport
protein that functions to excrete bile acids and other compounds, similar to MRP3 and
MRP4 (Boyer et al., 2006, Alrefai and Gill, 2007).
The association of elevated serum bile acid concentrations with drugs known to cause
hepatotoxicity led to the hypothesis that altered hepatic bile acid transport may be one
mechanism of drug-induced liver injury [DILI, (Funk et al., 2001b, Fattinger et al., 2001,
Funk et al., 2001a, Stieger et al., 2000, Kostrubsky et al., 2001, Roman et al., 1990,
Preininger et al., 1999)]. A number of hepatotoxic drugs, including bosentan, troglitazone,
and cyclosporine, inhibit BSEP-mediated bile acid transport in isolated in vitro systems
(Stieger et al., 2000, Funk et al., 2001b, Fattinger et al., 2001, Funk et al., 2001a, Byrne et
al., 2002).
TC, a model bile acid, has been used to evaluate the potential for drugs to inhibit bile acid
transport in the SCH system. Kostrubsky et al. demonstrated inhibition of TC transport in
human SCH with a set of structurally diverse compounds that were eliminated preferentially
via bile and known to cause liver toxicity in humans (cyclosporine A, bosentan, glyburide,
troleandomycin and CI-1034) (Kostrubsky et al., 2003). Kostrubsky and colleagues also
established that potent inhibition of TC efflux in SCH correlated with clinical reports of
liver toxicity, and elevated serum bile acids in rats (see below: Direct Assessment of
Cytotoxicity in SCH from Relevant Species). In a later study, Kostrubsky and colleagues
again confirmed that potent inhibition of TC efflux was predictive of the hepatotoxic
potential of nefazodone compared to a pair of non-toxic structural analogues, trazodone and
buspirone (Kostrubsky et al., 2006). Nefazodone was a potent inhibitor of TC transport in
Sf9-derived BSEP-expressing membrane vesicles; nefazodone also inhibited biliary
excretion of TC in rat SCH, and elevated serum bile acids when administered to rats in vivo.
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Nefazodone-associated decreases in protein synthesis as a measure of cellular toxicity, and
the role of phase I and phase II metabolism in the hepatotoxicity of nefazodone also were
evaluated, capitalizing on the ability of SCH to maintain a complex array of liver-specific
functions [see below: Hepatocyte Accumulation of Toxic Species, (Kostrubsky et al.,
2006)].
The role of impaired bile acid transport in troglitazone- and bosentan-associated
hepatotoxicity initially focused on BSEP-mediated canalicular efflux as the primary
mechanism leading to elevated serum bile acid concentrations (Funk et al., 2001b,
Kostrubsky et al., 2001, Fattinger et al., 2001, Funk et al., 2001a, Byrne et al., 2002). More
recently, Kemp et al. observed that while troglitazone and bosentan both decreased the BEI
of TC in SCH, consistent with Bsep inhibition, cellular accumulation of TC did not increase,
as might be expected (Kemp et al., 2005). In freshly isolated rat hepatocytes, 10 and 100 μM
troglitazone and bosentan each significantly decreased the uptake rate and accumulation of
the probe substrates TC (1 μM) and estradiol-17β-D-glucuronide (1 μM), an Oatp substrate,
consistent with inhibition of both Ntcp- and Oatp-mediated uptake mechanisms. Taken
together, these results suggest that drugs known to inhibit biliary excretion of bile acids also
may inhibit hepatic uptake, thus attenuating elevations of intracellular bile acid
concentrations and potential toxicity that may result. This phenomenon is analogous to
down-regulation of basolateral uptake mechanisms in cholestatic conditions, which
effectively minimizes accumulation of toxic bile acids inside hepatocytes (Zollner et al.,
2003, Lee et al., 2000, Lee and Boyer, 2000, Gartung et al., 1996, Gartung et al., 1997).
Preferential inhibition of basolateral uptake, as opposed to canalicular efflux, by drugs
would similarly reduce hepatocyte exposure to bile acids, while increasing bile acid
concentrations in the systemic circulation. This effect was explored by Leslie et al. as an
explanation for the species difference in bosentan toxicity between humans and rats [see
below: Direct Assessment of Cytotoxicity in SCH from Relevant Species, (Leslie et al.,
2007)].
Inhibition of bile acid transport was identified as a potential mechanism of antiretroviral-
associated hepatotoxicity using multiple model systems, including human and rat SCH
(McRae et al., 2006). BSEP-mediated biliary excretion, and NTCP- and OATP-mediated
uptake, of TC were inhibited differentially by the antiretroviral agents ritonavir, saquinavir,
and efavirenz, but not nevirapine. Potential hepatocyte accumulation of TC due to BSEP
inhibition was attenuated by concomitant inhibition of NTCP- and/or OATP-mediated
uptake of TC. The hepatotoxic potential of the antiretroviral agents could not be predicted
by rank order of TC inhibition in isolated uptake or efflux systems or SCH, suggesting that
“hepatotoxicity associated with antiretroviral therapy is likely complex and multifactorial,
such that inhibition of bile acid transport may be only one of several contributing factors
(McRae et al., 2006).”
An important application of the SCH model is in classifying compounds based on their
relative effect on bile acid uptake and/or efflux, which may provide useful information
concerning compounds that alter bile acid concentrations in vivo. For example, cyclosporine
A and glyburide decreased total accumulation (cells+bile), increased cellular accumulation,
and decreased BEI and Clbiliary of deuterium-labeled taurocholate (d8-TC), suggesting that
bile acid efflux was affected primarily (Ansede et al., 2009 in press). In contrast,
erythromycin-estolate, troglitazone and bosentan decreased d8-TC accumulation (both cells
+bile and cells), BEI and Clbiliary of d8-TC, suggesting that bile acid uptake was the
predominant pathway affected. Recently, the utility of a cassette dosing approach to identify
compounds that inhibit hepatic uptake and/or excretion of bile acids was demonstrated in rat
and human SCH (Wolf et al., 2009).
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Given the requisite overlap in substrate specificity of basolateral and canalicular hepatic
transport proteins necessary to mediate vectorial transport of bile acids, it is not surprising
that xenobiotics may modulate multiple hepatic bile acid transport mechanisms. The relative
effect of xenobiotics on both processes should be considered in order to predict the potential
consequences of modulating bile acid transport, disposition and homeostasis. SCH have
been used successfully to study hepatobiliary transport kinetics and mechanisms of both
hepatic uptake and biliary excretion of bile acids, simultaneously.
Drug-Drug Interactions in Hepatobiliary Transport
Hepatic clearance is an important pathway of elimination for many, if not most, drugs. Many
drugs and/or generated metabolites possess limited diffusion potential and rely on transport
proteins to mediate uptake into hepatocytes and/or excretion into bile. Thus, DDIs at the
level of hepatic uptake or efflux processes may be responsible for significant changes in
plasma or hepatocellular drug concentration-time profiles, with potential consequences for
therapeutic or toxic effects. Furthermore, identifying the extent and relevance of transporter-
mediated DDIs in human liver can be challenging, due to inaccessibility of the liver and bile
compartments. SCH combined with probe substrates exhibiting known transport protein
specificity offer the ability to identify transport proteins involved in the disposition of new
chemical agents, as well as the potential for new agents to be “victims” or “perpetrators” of
DDIs, in a physiologically-relevant model system.
Early work was performed in the Brouwer laboratory to optimize and validate the rat SCH
model for the study of P-gp-mediated biliary excretion using substrates such as rhodamine
123 and digoxin (Annaert et al., 2001). Addition of the P-gp (Mdr1) inhibitor, GF120918,
resulted in a 75% reduction in the BEI of rhodamine 123 and digoxin. Prediction of hepatic
P-pg-mediated drug interactions was later established in rat SCH using the high-affinity
probe substrate rhodamine 123 and various P-gp modulators (Annaert et al., 2001, Annaert
and Brouwer, 2005). The classical P-gp inhibitors verapamil and progesterone significantly
reduced the BEI and in vitro CLbiliary ofrhodamine 123, while inhibition by 100 μM
quinidine did not reach statistical significance. Quercetin, a P-gp activator, significantly
increased in vitro CLbiliary but not the BEI of rhodamine 123, reflecting the fact that cellular
accumulation was enhanced to a greater extent than excretion into bile. Treatment of SCH
with verapamil, rifampin and DEX was generally inconclusive in terms of P-gp induction.
However, results from DEX treatment implicated the involvement of an inducible element to
the basolateral uptake of rhodamine 123, which was supported further by inhibition of
rhodamine 123 uptake by digoxin, verapamil and quinidine, all documented substrates/
inhibitors of Oatp1a4. Indeed, Turncliff, et al. demonstrated that 48 h DEX treatment
induced protein expression and function of CYP3A1/2, Oatp1a4 and Mrp2, but not Mdr1
[see below: Drug-Hepatic Transport Protein Interactions (Turncliff et al., 2004)]. In rat
SCH, Mrp3 protein levels, determined by immunoblot analysis, were increased following
incubation with 1 mM phenobarbital for 72 hr; diluted bile from Wistar wild-type and TR-
rats also induced Mrp3, suggesting that one or more bile constitutents, other than
glucuronide or glutathione conjugates, were responsible for Mrp3 induction (Fig. 9a). Mrp2
protein was increased after incubation of rat SCH for 72 hr with selected nuclear receptor
agonists including cholic acid, chenodeoxycholic acid, phenobarbital and pregnenolone 16α-
carbonitrile (Fig. 9b).
Transport of the fluorescent probe CDF in rat liver was characterized using a number of
model systems (Zamek-Gliszczynski et al., 2003). Involvement of Mrp2 and Mrp3 was
confirmed in Mrp-expressing Sf9 membrane vesicles and IPLs from wild-type (WT) and
Mrp2-deficient TR− rats. Saturable CDF uptake was observed in WT rat SCH and probed
using nonspecific Oatp inhibitors, bromosulfophthalein (BSP) and probenecid, and specific
inhibitors digoxin (Oatp2), 100 μM para-aminohippurate (PAH) (Oat2), and 1 mM PAH
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(Oat3). Only BSP and probenecid inhibited uptake, suggesting CDF is taken up by an Oatp
isoform(s) other than Oatp2.
Annaert and colleagues characterized the kinetics of the fluorescent bile acid analogue
CGamF in rat SCH and assessed its utility as a probe for studying interactions with hepatic
uptake of endogenous or exogenous compounds using seven HIV protease inhibitors [PI,
(Ye et al., 2008)]. The known Oatp inhibitor, rifampin, reduced uptake of 1 μM CGamF by
70% (vs. 25% for 1 μM TC); removal of sodium produced no change in CGamF while
completely abolishing TC uptake. These observations confirm the well-described routes of
TC uptake (80% NTCP/20% OATPs) and suggested a complimentary role for CGamF as a
more sensitive probe for Oatp-mediated inhibition (Meier et al., 1997, Kouzuki et al., 2000).
Comparing the inhibitory potential of HIV PIs on the uptake of TC and CGamF in standard
and sodium-free conditions, a preferential interference with sodium-independent processes
(likely Oatps) emerged. Another notable observation was the striking potency of ritonavir
(IC50 = 0.25 μM) as an inhibitor of CGamF uptake compared to other PIs, indicating that
ritonavir may be a potent Oatp inhibitor, which is not detectable using TC in standard (+
sodium) conditions. The opportunity remains to elucidate the extent and possible
mechanisms of CGamF biliary excretion and potential for use as a probe of overall
hepatobiliary disposition.
Treijtel et al. utilized rat SCH to explore multiple processes responsible for the clearance of
the frequently co-administered HIV PIs saquinavir and ritonavir (Treijtel et al., 2009).
Saquinavir metabolism was significantly reduced by 5 μM ketoconazole, a known Cyp3a
inhibitor, and was even more sensitive to 1 μM ritonavir, confirming the role of metabolism
in the saquinavir-boosting effect of ritonavir coadministration. Biliary excretion of ritonavir
was investigated in rat SCH in the presence and absence of the P-gp inhibitors verapamil,
cyclosporine A and PSC833. Verapamil had little to no effect, but cyclosporine A and
PSC833 decreased ritonavir cellular accumulation ~50% due to decreased biliary excretion
and subsequently increased metabolism (Treijtel et al., 2009).
In a recent publication from Brouwer and coworkers, fexofenadine was evaluated as a probe
for studying hepatobiliary transport using a combination of pharmacokinetic modeling/
simulation of clinical and preclinical data from human SCH and rat isolated perfused livers
(IPLs) (Swift et al., 2009). Simulation studies indicated that systemic exposure to
fexofenadine in humans was sensitive to changes in hepatic uptake but not biliary efflux
rates. Inhibition of P-gp-mediated fexofenadine efflux in human SCH using GF120918 had
no effect on fexofenadine BEI or in vitro CLbiliary, further supporting simulation results.
However, fexofenadine is a known substrate of additional canalicular efflux proteins, MRP2
and BSEP, which cannot be selectively modulated with known chemical probes, but
presumably could compensate for P-gp inhibition. Of note, pharmacokinetic simulations
also indicated that inhibition of fexofenadine biliary excretion may result in a significant
(~20–60%) increase in hepatic exposure that is undetectable based on monitoring plasma
concentrations. These studies demonstrate the utility of SCH in combination with
pharmacokinetic modeling and simulation to explore and confirm mechanisms of DDIs.
The maintenance of cell polarity in vitro in the SCH model allows the unique ability to
simultaneously evaluate hepatic uptake and efflux processes at the basolateral membrane,
and biliary excretion processes at the canalicular membrane. A number of chemical probes
with known transport protein specificity and modulating effects (inhibition, activation,
induction) further facilitate the prediction of DDIs at the level of hepatic transport proteins.
Despite previous work to establish conditions for evaluating interactions with individual or
limited combinations of hepatic transport proteins, “a sufficiently diverse panel of model
substrates (and inhibitors) needs to be identified and profiled with respect to transporter
Swift et al. Page 15













affinity and interaction,” to enable “rapid and reliable screening for drug interaction and
cellular toxicity potential (Ye et al., 2008).”
Drug-Hepatic Transport Protein Interactions
Xeno- and endobiotics modulate transport proteins in a number of ways besides direct,
competitive interactions at the active site(s) responsible for binding and translocation of
substrates. Alterations in transport protein regulation at the level of transcription, translation
or post-translational modifications do not require direct interactions with the transport
protein. Both transcriptional and post-transcriptional regulation involves complex networks
of co-activators and co-repressors that provide multiple checkpoints and ensure balanced
activity of the pathways under normal conditions. The time scale of changes in transport
protein expression and activity are different, however. Transcriptional regulation produces
long-term changes in the total amount of transport protein that is available, while short-term
changes can only result from a re-arrangement of preexisting protein, which is mobilized as
a result of post-translational modifications.
A number of ligand-activated transcription factors have been associated with altered gene
expression of hepatic transport proteins in various in vitro and in vivo models, including the
pregnane X receptor (PXR/NR1I2), constitutive androstane receptor (CAR/NR1I3),
farnesoid X-activated receptor (FXR/NR1H4), retinoid X receptor alpha (RXRα/NR2B1),
aryl hydrocarbon receptor (AHR), peroxisome proliferator-activated receptors (PPARα,γ/
NR1C1,3), glucocorticoid receptor (GR), small heterodimer partner (SHP), liver X receptor
(LXR), nuclear factor E2-related factor 2 (Nrf2) and hepatic nuclear factor 1 alpha [HNF1α,
(Kast et al., 2002, Jigorel et al., 2006, Klaassen and Slitt, 2005, Aleksunes et al., 2009,
Staudinger et al., 2003, Kullak-Ublick and Becker, 2003). Similar to the transport proteins
themselves, nuclear receptors (NRs) are bound by an overlapping spectrum of endogenous
(hormones, bile acids) and exogenous (drugs, toxins) ligands (Parks et al., 1999, Moore et
al., 2000). Thus, drug-induced NR activation may result from direct drug interactions with a
given NR(s), or by altered intracellular disposition of endogenous agents, such as bile acids,
that are themselves NR ligands. Examples of drugs known to directly activate transcription
factors include: PXR - DEX, spironolactone; PPAR - fibrates; Nrf2 – ursodeoxycholic acid
(UDCA) (Maher et al., 2005, Cheng et al., 2005, Okada et al., 2008). Other drugs, such as
phenobarbital and rifampin, can alter transport protein function by both direct (competitive)
and indirect (up- or down-regulation) mechanisms (Patel et al., 2003, Lam et al., 2006).
Such complex and potentially confounding mechanisms present a serious challenge to
differentiate between transport protein induction and inhibition.
Although mechanistic work to investigate transcriptional regulation using SCH has been
minimal, routine sandwich-culture methodology takes advantage of maintained NR activity
in primary hepatocytes. DEX has long been used as a media supplement due to its
modulating effects on drug disposition mechanisms. DEX treatment is able to attenuate or
reverse changes in gene expression observed in cultured hepatocytes and, together with a
sandwich-cultured configuration, maintains expression of most relevant functions at near-
physiological levels. DEX treatment of rat SCH restores physiologic expression of Mdr2 and
Oatp1a4 mRNA by up-regulation, while maintaining Mdr1b and Mrp3 at baseline levels by
preventing their up-regulation (Luttringer et al., 2002). However, Mrp2 mRNA is up-
regulated by DEX beyond physiologic levels. The effects of DEX on protein expression and
function in rat SCH have been evaluated (Turncliff et al., 2004). Forty-eight hr DEX pre-
treatment increased expression of CYP3A1/2, Oatp1a4 and Mrp2, decreased expression of
Ntcp, and had no effect on Oatp1a1, Mrp3, Mdr1a/b and Bsep. Modest changes in the
transport of probe substrates were consistent with changes in protein expression, while
patterns of protein expression generally agreed with earlier gene expression data by
Luttringer et al., with the exception of Oatp1a4. Despite this example, mRNA and protein
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expression levels do not always correlate, and must be evaluated on a case-by-case basis for
transport proteins (Rodriguez-Antona et al., 2001, Ho et al., 2006).
Short-term regulation of hepatic transport protein trafficking to and from the plasma
membrane is mediated by post-translational modifications and second messenger signaling
pathways (Kipp et al., 2001, Anwer, 2004). “Signal” regions in the protein structure are
necessary for proper vesicle sorting and trafficking of newly-synthesized membrane-bound
proteins from the endoplasmic reticulum and Golgi network to final membrane locations.
These signals can take the form of specific peptide sequences or post-translational
modifications, such as glycosylation. The role of glycosylation in Mrp2 expression,
localization and function was investigated in rat SCH (Zhang et al., 2005b). Although the
amount of cellular Mrp2 protein did not change, a gradual increase (~10kDa by western
blot) in molecular weight over days in culture correlated with increased staining at the
canalicular membrane by confocal microscopy, on day 4, relative to diffuse intracellular and
ER co-localization at day 0 or day 1 in culture. Molecular weight and canalicular
localization were decreased by treatment with tunicamycin, an inhibitor of glycosylation.
Cellular trafficking also is mediated by other modification “signals,” such as phosphate or
ubiquitin residues, on transport proteins themselves, or on the chaperone proteins that move
them around within the cell (Glavy et al., 2000). The cellular machinery responsible for
modifying and mobilizing proteins is under the control of a complex series of second
messenger pathways. A number of second messengers have been associated with changes in
transport protein expression, localization and function, including cyclic AMP (cAMP),
cGMP, intracellular Ca2+, phosphoinositol-3-kinase (PI3K), protein kinases A, B and C
(PKA, PKB, PKC), and p38 mitogen activated protein kinase [MAPK, (Anwer, 2004,
Roelofsen et al., 1998, Misra et al., 1998, Kubitz et al., 2004)]. The effect of cAMP and
PKC activators, glucagon and phorbol 12-myristate 13-acetate (PMA), on Mrp3/MRP3
regulation was investigated in rat and human SCH and rat IPLs (Chandra et al., 2005).
Glucagon increased CDF excretion and Mrp3/MRP3 localization at the basolateral
membrane in both rat and human SCH, while PMA had no effect. Glucagon also increased
CDF efflux in rat IPLs, suggesting that cAMP effects are recapitulated in the SCH model
and similar across species. PMA decreased CDF efflux in rat IPLs, consistent with known
down-regulation mediated by PKC activation, though it is unclear why PMA had no effect
in SCH. These trafficking pathways can play a significant role in transport protein function,
and may be modulated by xenobiotics, potentially including the recently developed family
of kinase inhibitors (Katayama et al., 2007). SCH clearly demonstrate functional post-
translational and second messenger pathways, although further characterization is needed.
Use of Sandwich-Cultured Hepatocytes to Predict Drug-Induced Liver
Injury and Examine Mechanisms of Hepatotoxicity
DILI is historically one of the most common reasons that drugs fail in development or are
removed from the market after being approved (Lee, 2003). Therefore, experimental models
to better predict DILI are still needed. Furthermore, when DILI is predicted, it would be
beneficial to understand the mechanism(s) of hepatotoxicity in order to assist in the design
and testing of alternate compounds to circumvent toxic potential. In theory, a useful in vitro
model would recapitulate relevant liver functions and mechanisms of hepatotoxicity, and
resemble the in vivo situation as closely as possible. As detailed above, SCH are a unique in
vitro system that maintains specific hepatic cytomorphology and function relevant to drug
metabolism, disposition, and toxicity, and thus, closely resembles the in vivo setting.
Swift et al. Page 17













Direct Assessment of Cytotoxicity in SCH from Relevant Species
It is an unfortunate fact that many hepatotoxic compounds go unrecognized in preclinical
toxicology studies using animal models or screening for cytotoxicity. Species differences in
metabolism or transport pathways can lead to marked differences in tolerance to toxic
substances. In addition, in vitro models may not recapitulate the complex processes that
often lead to gross toxicity. Therefore, the choice of preclinical toxicity models and
endpoints can influence predictability of adverse events in humans.
SCH have contributed a great deal to our understanding of hepatotoxicity caused by
inhibition of bile acid transport that may go unrecognized in animal studies. Kostrubsky and
colleagues assessed the effects of numerous hepatotoxicants on human SCH [see above:
Inhibition of Bile Acid Transport by Drugs (Kostrubsky et al., 2003, Kostrubsky et al.,
2006)]. They established, for a series of macrolide antibiotics, that potent inhibition of TC
efflux in human SCH correlated with clinical reports of liver toxicity, suggesting that rank
order of in vitro TC inhibition may be predictive of hepatotoxic potential in vivo. Although
preclinical rodent toxicity studies were previously negative, Kostrubsky and coworkers
demonstrated that two inhibitors of TC transport in human SCH (CI-1034 and glyburide)
caused a transient, 2.4-fold increase in serum bile acids when dosed individually in vivo in
rats; coadministration resulted in a synergistic (6.8-fold) increase. Later, the effect of
nefazodone was compared to its nontoxic structural analogues, buspirone and trazodone, in
human SCH and intact rats (Kostrubsky et al., 2006). Cellular toxicity was assessed in SCH
by measuring a decrease in protein synthesis after drug treatment and pulse labeling
with 14C-leucine. Toxicity was associated exclusively with nefazodone, and correlated with
accumulation of parent drug (see below: Hepatocyte Accumulation of Toxic Species).
Nefazodone, but not buspirone, elevated serum bile acids in rats 1 hr after dosing, which
was resolved by 24 hr. These studies provide several preclinical alternatives with the
potential to identify hepatotoxic compounds that act by different mechanisms and
demonstrate species differences.
Mechanistic understanding of species differences in hepatotoxicity has the potential to
identify new opportunities for predicting toxic events that previously went undetected until
reaching the clinic. The hepatotoxic potential of HIV PIs was compared in human and rat
SCH, with similar patterns of TC inhibition, although PIs appeared to be more potent
inhibitors of rat than human TC biliary efflux (McRae et al., 2006). Rank order of inhibition
of TC efflux was not able to predict PI hepatotoxicity, as it did for macrolide antibiotics
(Kostrubsky et al., 2003). However, it was shown that potential accumulation of bile acids
due to PI-mediated BSEP inhibition was attenuated by concomitant inhibition of TC uptake
in human SCH, similar to the findings of Kemp et al. in rat SCH (Kemp et al., 2005). In
another publication from Brouwer and coworkers, this effect was explored as an explanation
for the species difference in bosentan toxicity between humans and rats (Leslie et al., 2007).
Although bosentan inhibited uptake as well as efflux in human SCH, resulting in decreased
TC accumulation, inhibition of bile acid uptake is not expected at relevant concentrations in
human. However, bosentan-mediated inhibition of Na+-dependent TC uptake was
approximately 6− and 30-fold more potent in rat vs. human suspended hepatocytes and
NTCP-/Ntcp-transfected HEK cells, respectively. Thus, preferential inhibition of rat Ntcp
remains a plausible explanation for the observed resistance of rats to bosentan-induced
hepatotoxicity observed clinically in humans.
Similarly, differential effects on TC disposition were observed in the seminal publication
establishing sandwich-cultured conditions for dog and monkey hepatocytes (Rose et al.,
2006). Glyburide abolished TC efflux in dog SCH, with no effect on efflux in monkey SCH.
Conversely, glyburide inhibited TC uptake in monkey but not dog SCH, while cyclosporin
A inhibited efflux but not uptake similarly in both dog and monkey SCH. These marked
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differences in TC inhibition underscore potential differences in observed hepatotoxic
potential across preclinical species.
SCH recently were evaluated for the potential to assess hepatobiliary disposition of copper
(Ansede et al., 2009). Copper (Cu) is an essential nutrient necessary for the activity of
various enzymes, but also can accumulate to toxic levels when Cu elimination is disrupted
by drugs or genetic disorders, such as in Wilson's Disease, which is characterized by
massive Cu accumulation in lysosomes and lack of excretion in bile, the major route (85%)
of Cu elimination. Hepatic Cu disposition is fairly well characterized: basolateral uptake is
mediated by Cu transporter 1 (CTR1), while the ATP-dependent ATP7B transports Cu into
trans-Golgi Network (TGN) vesicles for incorporation into ceruloplasmin and, apical
membrane vesicles for biliary excretion (via exocytosis) of excess Cu. Cu transport was
evaluated in rat, dog and human hepatocytes. CTR1/Ctr1 and ATP7B/Atp7b expression was
confirmed in hepatocytes from all species by western blot analysis, with slight changes in
expression observed in some species following exposure to Cu-supplemented media. CTR1/
Ctr1 expression was decreased slightly in human and rat SCH, while Atp7b was elevated
slightly in rat SCH; all changes were consistent with a protective role of reducing hepatic
exposure in the presence of excess Cu. Relative differences in endogenous Cu levels in SCH
from rat, dog and human (17.2, 490 and 43.5 ng/well, respectively) were consistent with
published values for Cu content in livers of intact animals from corresponding species
(3.56–5.56, 57.32–173.3, 6.2 μg/g in rat, dog and human, respectively). Increased uptake
and efflux were observed with increases in Cu concentration and incubation time,
confirming functional Cu transport and the potential for SCH to serve as a useful model to
study the role of transport in Cu homeostasis.
Various assays have been used to assess viability in cytotoxicity studies as a direct measure
of toxic effects. The utility of five such assays was compared in rat SCH to measure the
toxic effects of increased bile acid accumulation resulting from inhibition of bile acid efflux
by troglitazone, bosentan and glibenclamide (Kemp and Brouwer, 2004). The neutral red
assay was not amenable for use in SCH due to crystal formation, while the LDH, MTT,
propidium iodine and alamar blue assays were useful for viability assessment, having low
variability and correlating well with morphologic changes observed by light microscopy.
The LDH and propidium iodide assays are the methods of choice because they are amenable
to multiple time point measurements and high-throughput analysis.
Toxicogenomics is another approach to measure compound-induced changes in multiple
genes and signaling pathways, with the potential to extrapolate in vitro toxicology
experiments to the in vivo situation. Comparison of gene expression and traditional
toxicology assays, both in vitro and in vivo, reveals that genes are affected earlier and at
lower dose levels than needed to detect toxicity by traditional measures (Heinloth et al.,
2004, Kienhuis et al., 2006). Thus, gene expression changes may be more sensitive
indicators of potential adverse effects. The primary limitation of most hepatic in vitro assays
used in toxicogenomics studies is the loss of liver-specific functions. Among in vitro
systems, SCH exclusively maintain polarized morphology and the panoply of liver-specific
functions reflective of the in vivo situation. This includes the ability to induce enzyme
systems, which can be used to study induction as a mechanism of DDIs or toxicity, as well
as enhance enzyme activity to study compounds for which toxicity depends on activation by
P450s or other enzyme systems. In one example, SCH were maintained in standard medium
or medium modified with known P450 inducers phenobarbital, DEX and β-naphthoflavone
to study coumarin-induced cytotoxicity and gene expression profiles (Kienhuis et al., 2006).
Coumarin metabolism and resulting cytotoxicity correlated with in vivo toxicity studies only
in hepatocytes maintained in modified culture medium, while gene expression changes in
the modified system were also much more reflective of in vivo studies. This demonstrates
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that even when standard conditions for sandwich-culture are not entirely reflective of the
desired endpoint(s), maintenance of liver-specific functions, such as induction, allows the
model to be modified to recapitulate the desired effect observed in vivo.
Hepatocyte Accumulation of Toxic Species
Accumulation of toxic compounds within hepatocytes can occur by a number of
mechanisms, including efficient uptake, inefficient or compromised excretion, and
sequestration into subcellular compartments. Accumulation of bile acids to toxic levels by
inhibition of canalicular efflux, including the potential attenuation of accumulation by
concomitant inhibition of hepatic uptake, has been discussed extensively above.
Returning again to the study by Kostrubsky and colleagues in 2006, accumulation of parent
nefazodone correlated with toxicity in human SCH (Kostrubsky et al., 2006). Total protein
synthesis, determined by pulse-labeling with 14C-leucine, was reported as a measure of
toxicity. Nefazodone, but not buspirone or trazodone, resulted in decreased protein synthesis
after treatment for 6 hr with 10, 50 and 100 μM of the antidepressants. The time course of
nefazodone toxicity was evaluated by treating SCH with nefazodone (10, 50 and 100 μM)
for 1, 6 and 24 hr. Decreased protein synthesis was detected at 1 hr for all doses of
nefazodone. At 24 hr, protein synthesis returned to normal for 10 μM but not 50 or 100 μM
nefazodone. Further analysis by LC/MS/MS for nefazodone and metabolites in media
revealed a 90% decrease in parent nefazodone at 24 hr after treatment with 10 μM; no
decrease in nefazodone following incubation with 50 or 100 μM suggested that metabolism
was compromised or insufficient for higher doses, resulting in prolonged exposure to parent
compound, a sustained decrease in protein synthesis, and morphological cell death by
microscopy. This effect was confirmed by treating cells with 10 μM nefazodone + 1 mM 1-
aminobenzotriazole (ABT, a P450 inhibitor), resulting in accumulation of parent
nefazodone, decreased formation of conjugated metabolites, and lack of recovery in protein
synthesis at 24 hr.
Trebectadin cytotoxicity and attenuation by DEX pretreatment were successfully
recapitulated in rat SCH, allowing investigation of the mechanism(s) by which DEX
attenuates hepatotoxicity in rats and humans (Lee et al., 2008). DEX-mediated induction of
Cyp3A and Mrp2 were both postulated mechanisms of hepatoprotection. Although a 75%
reduction in biliary excretion in Mrp2-deficient TR− versus wild-type rat IPLs confirmed the
involvement of Mrp2 in the biliary excretion of trebectadin, TR− rat SCH were surprisingly
more resistant to trebectadin-induced cytotoxicity. Increased expression and activity of P450
enzymes, glutathione (GSH) and basolateral Mrp3 in TR− rats were proposed as possible
explanations. Pre-treatment with 500 μM buthionine sulfoximine (BSO), which depletes
cellular GSH, resulted in an unexpected decrease in cytotoxicity. Western blot analysis of
cell lysates from BSO-treated and control SCH revealed that Mrp2, Mrp3 and Mrp4 protein
were increased by 1.5±0.7-, 1.9±0.4- and 3.1±0.7-fold, respectively. Results of this study
suggest that trebectadin-mediated cytotoxicity can be attenuated by numerous mechanisms
that reduce cellular accumulation of intact trebectadin, whether by DEX-mediated increases
in CYP3A metabolism and Mrp2 excretion, or markedly increased basolateral excretion due
to up-regulation of Mrp3 and/or Mrp4 in the presence of BSO. Rat SCH were used
successfully to reproduce cytotoxicity of trebectadin observed in intact animals and explore
the role of transport proteins in attenuation of cytotoxicity.
Human SCH were employed to determine the role of nucleoside transporters in the
hepatobiliary disposition of nucleosides and nucleoside drugs in the liver (Govindarajan et
al., 2008). Protein expression and localization of equilibrative and concentrative nucleoside
transporters (ENTs and CNTs) in human SCH were determined, and mRNA expression was
compared to human liver samples. Expression levels of ENT2 and CNT2 mRNA in SCH
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format were similar to intact liver, but 2-D cultures (no overlay) resulted in significantly
lower levels of ENT2 and CNT2 mRNA. Uptake into hepatocytes and elimination, by
metabolism and/or vectorial transport into bile canaliculi, were demonstrated for 5
nucleosides and nucleoside analogues [guanidine, thymidine, ribavirin, formycin B and
fialuridine (FIAU)]. Conditions were established to allow deconvolution of the relative
contribution of individual transporters to the overall uptake of each substrate, which was
varied and substrate-dependent. However, common patterns were observed, such as the
significant (if not predominant) role of ENT1 for all substrates, and an inverse relationship
between the extent of metabolism and excretion into bile. An example of the applicability of
this system was the high extent of FIAU accumulation that, coupled with previous data
detailing its mitochondrial transport and resulting cytotoxicity, may explain the significant
hepatotoxicity of this drug (Lai et al., 2004). A more recent study extended the scope of
ENT expression data to include ENT3, which displayed a higher level of mRNA expression
than CNT1 and ENT1 in human liver samples and SCH; based on immunostaining, ENT3
was localized exclusively in the cytoplasm, co-localized with markers of both mitochondrial
and non-mitochondrial compartments (Govindarajan et al., 2009).
Rat and human SCH recently were reported as a model to determine the formation of acyl
glucuronides and covalent binding to cellular proteins (Dong and Smith, 2009).
Glucuronidation and protein adduct formation were monitored following exposure of rat
SCH to benoxaprofen, a known hepatotoxicant, and two related NSAIDs, flunoxaprofen and
ibuprofen. Glucuronide and protein adducts were detected in the order: benoxaprofen >
flunoxaprofen > ibuprofen. Despite this correlation, modulation of glucuronidation and
oxidative metabolism pathways suggested that covalent binding to proteins was mediated
only partly by reactive glucuronide formation and not at all by oxidative metabolites,
leaving an unknown component of protein adduct formation. Although glucuronidation rates
varied between donors of human SCH, as might be expected, glucuronide and protein adduct
formation were greatest for benoxaprofen. These studies demonstrate the utility of SCH for
determining relative risk of forming protein adducts from reactive acyl glucuronides.
Hepatic Transport Protein Knockdown and Knockout Models
RNA interference (RNAi) of single or multiple transport proteins is a powerful tool to
explore potential rate-limiting steps in hepatic transport and consequences (“worst-case
scenario”) of altered hepatic transport protein function caused by disease states, DDIs or
polymorphisms. This approach is particularly useful to evaluate transport proteins for which
no “specific” inhibitor has been identified. Synthetic small interfering RNA (siRNA) was
transfected successfully into rat SCH to specifically knock down the efflux transporters
Mrp2 and Mrp3 (Tian et al., 2004). The extent of protein modulation (~50% knockdown)
agreed well with changes in activity, as determined by CDF disposition. More recently,
adenoviral vectors expressing short hairpin (sh)RNA targeting Bcrp were delivered
successfully into rat SCH to specifically, efficiently and sustainably suppress Bcrp protein
expression and activity (Yue et al., 2009). Bcrp knockdown decreased nitrofurantoin BEI
and CLbiliary to 11 and 14% of control, respectively. Digoxin, a P-gp substrate, was not
affected by Bcrp knockdown; however, GF120918 significantly reduced the biliary
excretion of both digoxin and nitrofurantoin, consistent with known inhibition of both P-gp
and Bcrp. These studies demonstrated that knockdown of specific transport proteins in SCH
is possible, and mimics the effect of inhibitors on substrate disposition.
Hepatocytes from animals with transport protein-deficient genotypes, such as Mrp2-
deficient TR− rats may be cultured in a sandwich configuration (Abe et al., 2008, Lee et al.,
2008). Another promising source of hepatocytes for SCH studies is from genetically-
modified mouse strains such as Mrp2/Abcc2−/− knockout mice. However, care must be
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taken to fully characterize these models, since loss of expression or function of one transport
protein may change the route and/or extent of excretion due to compensatory changes in
drug metabolizing enzymes or transport proteins. For example, Nezasa et al. demonstrated
that hepatic Mrp3/Abcc3 protein levels were approximately 60% higher in Mrp2/Abcc2−/−
mice compared to wild-type mice, corresponding to a 4-fold increase in the rate of
basolateral CDF excretion (Nezasa et al., 2006). In addition, it was established recently that
Mrp2-deficient TR− rats also partially lack full Bcrp expression and activity (Abe et al.,
2008). SCH, coupled with knockdown or knockout technology, represent a useful in vitro
model to determine the contribution of specific canalicular or basolateral transport proteins
to drug/metabolite disposition, and to examine the impact of loss-of-function of transport
proteins on drug/metabolite disposition.
Future Challenges
Culturing hepatocytes in a sandwich configuration to maintain cell viability, polarized
architecture and liver-specific function has led to significant advances in our understanding
of hepatic transport processes and related interactions leading to pharmacokinetic and
pharmacodynamic changes in endo- and xenobiotic disposition and hepatotoxicity. Despite
these advances, a number of opportunities remain to further develop and characterize the
SCH model. The limited availability of fresh hepatocytes from a variety of species,
particularly human, has stimulated interest in the use of cryopreserved SCH. Unfortunately,
not all batches of cryopreserved hepatocytes are suitable for culturing in a sandwich
configuration, due to limitations in cell attachment and loss of transport protein expression,
localization and/or function. Further research is needed to improve the cryopreservation
process to yield hepatocytes amenable for SCH studies. Modifications of the culture system
to incorporate sinusoidal flow and exteriorized bile flow may improve hepatocyte
morphology and help retain liver-specific properties. Optimization of culture medium to
maintain in vivo-like cytochrome 450 activity in addition to transport function would
enhance utility of the model. Further use of this model as a screening tool in drug
development to evaluate metabolite formation and routes of excretion, predict in vivo biliary
clearance, and evaluate DDIs in hepatobiliary transport will undoubtedly yield a wealth of
new information about species differences in hepatic transport, mechanisms of DILI, and
xenobiotic-transport interactions.
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Mrp2 Multidrug Resistance-associated protein 2
Mrp3 Multidrug resistance-associated protein 3
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Bsep Bile salt export pump
Mdr1 Multidrug resistance p-glycoprotein
CDF 5(and 6)-carboxy-2',7'dichlorofluorescein
NTCP Sodium taurocholate cotransporting polypeptide
HBSS Hanks' balanced salt solution
LDH Lactate dehydrogenase
EHBR Eisai hyperbilirubinemic Sprague-Dawley rats
Bcrp breast cancer resistance protein
RNAi RNA interference
siRNA small interfering RNA
shRNA short hairpin RNA
CLF cholyl-lysyl-fluorescein
CGamF Cholylglycylamido-fluoroscein
Oatp Organic anion transporting polypeptide
DDI Drug-drug interaction
IPL Isolated perfused liver
OSTα/β Organic Solute Transporter






PXR/NR1I2 pregnane X receptor
CAR/NR1I3 constitutive and rostane receptor
FXR/NR1H4 farnesoid X-activated receptor
RXRα/NR2B1 retinoid X receptor alpha
AHR aryl hydrocarbon receptor
PPARα,γ/NR1C1,3 peroxisome proliferator-activated receptors
GR glucocorticoid receptor
SHP small heterodimer partner
LXR liver X receptor
Nrf2 nuclear factor E2-related factor 2
HNF1α hepatic nuclear factor 1 alpha
NRs nuclear receptors
UDCA ursodeoxycholic acid
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PKA, PKB, PKC protein kinases A, B and C
MAPK p38 mitogen-activated protein kinase
PMA phorbol 12-myristate 13-acetate
GSH glutathione
DMEM buthionine sulfoximine, BSO Dulbecco's modified Eagle's medium
BC/MG biocoat/matrigel
GC/GC gelled collagen/gelled collagen
M3G morphine 3-glucuronide
IPL isolated perfused liver
ER endoplasmic reticulum
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Figure 1. Confocal microscopy images revealing immunofluorescent localization of Mrp2 (green)
on the canalicular domain and Mrp3 (red) on the basolateral domain in day 4 rat SCH
This figure was published by Zhang et al. (Zhang et al., 2005b), and reprinted with
permission from the American Society for Pharmacology and Experimental Therapeutics.
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Figure 2. Relationship between in vitro intrinsic Clbiliary values generated for compounds in rat
and human SCH with in vivo Clbiliiary data
Rat in vivo Clbiliary of 11 compounds vs. predicted in vitro Clbiliary data generated in rat SCH
[blue; r2=0.99; (Liu et al., 1999a)] and human in vivo Clbiliary of three compounds vs.
predicted in vitro Clbiliary data generated in human SCH [green; (Ghibellini et al., 2007)].
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Figure 3. CDF fluorescence microscopy images of rat (A), dog (B), monkey (C), and human (D)
SCH
in six-well plates (maintained in DMEM for 4–7 days). SCH were incubated with 2 μM
CDF diacetate for 10 min prior to imaging.
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Figure 4. Light (A & C) and CDF fluorescence (B & D) microscopy images of wild-type (A & B)
andAbcc2−/− [(Mrp2 knockout); C & D] mouse SCH
cultured on six-well Biocoat™ plates with rat tail gelled collagen overlay (maintained in
DMEM for 4 days). Mouse SCH were incubated with 2 μM CDF diacetate for 10 min prior
to imaging. Data generated by Dr. Xianbin Tian.
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Figure 5. Transport protein levels over days in culture in rat and human SCH
Representative immunoblots of transport proteins in rat and human hepatocytes cultured in
six-well Biocoat™ plates with Matrigel™ overlay and maintained with DMEM for 4 or 6
days, respectively. β-actin was used as a loading control. Immunoblots of rat Mrp3 and
Mrp4 were provided by Tracy Marion; rat Ntcp immunoblots were provided by Katie Paul;
rat Bcrp, Bsep, P-gp, and human MRP3 and MRP4 immunoblots were provided by Dr. Wei
Yue. Select data were published previously: rat Mrp2 (Zhang et al., 2005b); rat Oatp1a1,
Oatp1a4, P-gp, and for human OATP1B1, OATP1B3, MRP2 and P-gp (Hoffmaster et al.,
2004); reproduced, in part, with kind permission from the American Society for
Pharmacology and Experimental Therapeutics, and from Springer Science and Business
Media, respectively.
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Figure 6. Schematic depicting calculation of substrate accumulation in hepatocytes and bile
canalicular networks of SCH
SCH are preincubated in Ca2+-containing HBSS (standard buffer) or Ca2+-free HBSS (Ca2+-
free buffer) to disrupt tight junctions sealing the bile canalicular spaces (Liu et al., 1999b,
Liu et al., 1999c). Subsequently, cultures are rinsed and substrate uptake in SCH is
determined in standard buffer for a designated period of time within the linear range of
uptake (typically 10 min). In SCH preincubated with standard buffer, substrate is taken up
into SCH and available for excretion into the bile canalicular networks; substrate
accumulation (cells+bile) is determined at the end of the uptake period. In SCH
preincubated with Ca2+-free buffer to open tight junctions, substrate excreted into the bile
canalicular networks is released into the medium; substrate accumulation (cells) is
determined at the end of the uptake period. The mass of substrate excreted into the bile
canalicular networks during the uptake period is estimated as the difference in accumulation
in SCH with intact and disrupted tight junctions [(cells+bile) − (cells)].
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Figure 7. Schematic depicting calculation of canalicular and basolateral efflux of substrate in
SCH
Step 1: SCH are preincubated with substrate (▲) in Ca2+-containing HBSS (standard buffer)
to preload the cells; substrate is taken up into SCH and excreted into the bile canalicular
networks. Step 2: Cultures are rinsed in standard buffer, or Ca2+-free HBSS (Ca2+-free
buffer) to disrupt tight junctions sealing the bile canalicular space. Step 3: SCH are
incubated in their respective buffers, and aliquots are taken at designated time points for no
longer than 30 min. In SCH rinsed and incubated with standard buffer, substrate efflux
occurs across the basolateral membrane only. In SCH rinsed and incubated with Ca2+-free
buffer to open tight junctions, substrate efflux occurs across the basolateral and canalicular
membrane. The canalicular efflux is estimated as the difference in efflux between SCH with
disrupted and intact tight junctions [(basolateral + canalicular efflux) − (basolateral efflux)].
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Figure 8. Effect of incubation time in standard HBSS (dark bars) and Ca2+-free HBSS (white
bars) on viability of rat SCH
Day 4 SCH from wild-type Wistar rats in six-well Biocoat™ plates with Matrigel™ overlay
were incubated with 1.5 mL/well of warm standard HBSS for 20 min, followed by two
rinses with 2 mL/well warm standard HBSS or Ca2+-free HBSS, and incubation with 1.5
mL/well of the same buffer. Cytotoxicity was determined by measuring lactate
dehydrogenase (LDH) release into the respective HBSS buffers after designated times using
a cytotoxicity kit according to the manufacturer's instruction (Roche, Indianapolis, IN; Each
bar represents the mean ± SEM; n=3 livers in triplicate; p<0.05).
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Figure 9. Immunoblot analysis of the influence of modulators on (a) Mrp3 and (b) Mrp2 protein
in rat SCH
Rat SCH cultured for 72 hr with (a) phenobarbital (1 mM) or diluted bile (1:100) from TR−
and Wistar control rats exhibited increased Mrp3 protein. Data generated by Dr. Peijin
Zhang; (b) Mrp2 protein was increased after incubation of rat SCH for 72 hr with selected
nuclear receptor agonists including cholic acid (CA; 200 μM), chenodeoxycholic acid
(CDC; 200 μM), phenobarbital (PB; 1000 μM) and pregnenolone 16α-carbonitrile (PCN; 10
μM). Data generated by Dr. Yong Hae Han.
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Table 2
In Vitro CLbiliary Scaling Factors
Species Protein Concentration per Gram ofLiver Tissue (mg/g) # of Hepatocytes/Gram of Liver Tissue (10
6cell/g) Grams of Liver Tissue/kg BodyWeight (g/kg)
Human 90(3), 32(5) 139(3), 107(4), 99(5), 120(7) 25.7(1)
Rat 200(2), 112(3) 117(3), 96(6) 120(7) 40(1)
Mouse 115(3) 135(3) 87.5(1)
Monkey 30(1)
Dog 103(3) 215(3), 165(6), 240(7) 32(1)
(1)






(Wilson et al., 2003)
(5)
(Barter et al., 2007)
(6)
(Smith et al., 2008)
(7)
(Bayliss et al., 1999)
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